Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Pandion Therapeutics, Inc. (PAND)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-20Dec-31-19
   10-K10-K
Revenue  8.81.0
            Revenue growth  807.9% 
Operating expenses    
Research and development  33.918.2
General and administrative  12.85.0
    Total operating expenses  46.723.2
    Loss from operations  -37.9-22.2
            Operating margin  -432.0%-2297.7%
Interest income  0.10.3
Interest expense  -0.30.0
Fair value adjustments to convertible note  0.10.1
    Net loss  -38.1-21.9
Change in redemption value of redeemable convertible preferred shares  -4.9-4.0
    Net loss attributable to common shares – basic and diluted  -43.0-25.9
   
Net loss per common share, basic and diluted  ($3.17)($25.00)
   
Weighted-average number of shares used in computing net loss per common share, basic and diluted  13.61.0

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy